Audentes Therapeutics Inc (BOLD) Given Average Recommendation of “Buy” by Analysts
Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) have received a consensus rating of “Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $37.00.
A number of equities analysts recently issued reports on BOLD shares. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 17th. BidaskClub downgraded shares of Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 6th. Bank of America reissued a “buy” rating and issued a $33.00 price target (up from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. Leerink Swann reissued an “outperform” rating and issued a $29.00 price target (up from $22.00) on shares of Audentes Therapeutics in a research note on Wednesday, November 15th. Finally, Raymond James Financial started coverage on shares of Audentes Therapeutics in a research note on Thursday, October 12th. They issued a “market perform” rating for the company.
In other Audentes Therapeutics news, SVP Mary Newman sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $26.84, for a total transaction of $268,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Louis G. Lange sold 18,000 shares of the firm’s stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total transaction of $555,840.00. The disclosure for this sale can be found here. Insiders have sold 36,000 shares of company stock valued at $1,052,480 in the last ninety days. Insiders own 47.30% of the company’s stock.
Audentes Therapeutics (NASDAQ BOLD) opened at $33.65 on Thursday. Audentes Therapeutics has a one year low of $13.90 and a one year high of $41.80. The stock has a market cap of $957.16 and a PE ratio of -9.67.
Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.88). equities analysts anticipate that Audentes Therapeutics will post -3.5 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/audentes-therapeutics-inc-bold-given-average-recommendation-of-buy-by-analysts/1802126.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.